Valerian to Improve Sleep in Patients With Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00070928
Recruitment Status : Completed
First Posted : October 13, 2003
Last Update Posted : July 26, 2006
Information provided by:
National Center for Complementary and Integrative Health (NCCIH)

October 9, 2003
October 13, 2003
July 26, 2006
September 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00070928 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Valerian to Improve Sleep in Patients With Parkinson's Disease
Polysomnographic Assessment of Alternative Treatments for Sleep Disturbance in Parkinson's Disease
The purpose of this trial is to test the short-term effectiveness of valerian, a medicinal herb, to improve sleep in patients with Parkinson's disease (PD).

Patients with PD have exceptionally poor sleep. Sleep in patients with PD is characterized by excessive activity in surface electromyographic (EMG) recordings from many different muscle groups. Despite sleep disturbances, approximately 50% of patients experience a transient (1 to 3 hour) reduction in waking motor symptoms upon arising in the morning. This effect has been termed Sleep Benefit. This study will evaluate the effects of valerian, a medicinal herb, on the sleep of patients with PD.

This is a 17 day study where participants will be evaluated by polysomnography on days one, two, three, sixteen and seventeen.. Polysomnographic measurements will include customary variables such as total sleep time, sleep efficiency, and sleep latency, as well as EMG measures of periodic and isolated muscle activity during sleep. Participants will be required to keep a detailed sleep log of their self reported sleep characteristics across the entire 17 study nights. Outcomes will include measures of both nocturnal sleep and waking motor function. Assessments of motor function will be made the morning immediately following Nights 3 and 17 in order to test for improvement related to improved sleep. On the morning following Night 17, participants are provided with a one-week supply of valerian in an Open Label extension. Participants are provided an additional Sleep Log for this week and asked to return the Sleep Log when they complete the Open Label phase.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Insomnia
  • Parkinson's Disease
Drug: valerian
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
June 2006
Not Provided

Inclusion Criteria

  • Idiopathic Parkinson’s disease
  • Willing to undergo overnight, in-lab polysomnography
  • Sufficient literacy to allow completion of sleep logs
  • Stable doses and timing of all Parkinsonian medications during the course of the trial

Exclusion Criteria

  • Dementia
  • Parkinsonism secondary to toxic, infectious, or other medical conditions
  • History of stroke, cerebellar disease, or progressive supranuclear palsy
  • History of liver or renal disease
  • History of duodenal or bladder obstruction
Sexes Eligible for Study: All
30 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
R01AT000611-01( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Not Provided
Not Provided
National Center for Complementary and Integrative Health (NCCIH)
Not Provided
Principal Investigator: Donald L. Bliwise, PhD Emory University
National Center for Complementary and Integrative Health (NCCIH)
July 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP